Literature DB >> 15570000

Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.

Hisatsugu Goto1, Seiji Yano, Yuka Matsumori, Hirohisa Ogawa, David C Blakey, Saburo Sone.   

Abstract

PURPOSE: ZD6126 is a novel vascular-targeting agent that selectively disrupts the tubulin cytoskeleton of endothelial cells. In the immature vessels characteristic of tumor vasculature, this leads to endothelial cell contraction, blood vessel congestion, and, consequently, tumor cell death. ZD6126 has been shown to delay tumor growth in a range of xenograft models. The antitumor effect of ZD6126 can be increased in combination with cisplatin or radiation therapy, although the precise mechanism of this enhancement has not been demonstrated. ZD6126 treatment has also been shown to inhibit lung metastasis, and the present study has explored the potential to increase the antimetastatic effect of ZD6126 by combining with cisplatin, and the underlining mechanism has been investigated. EXPERIMENTAL
DESIGN: Human lung adenocarcinoma PC14PE6 cells were injected into the tail vein of nude mice. Five weeks after injection animals were treated with ZD6126 (200 mg/kg i.p.), cisplatin (6 mg/kg i.v.), or a combination of the two agents. The animals were sacrificed 24 hours later, and the extent of lung metastases and the presence of apoptotic cells were assessed.
RESULTS: Histologic analysis revealed that the ZD6126/cisplatin combination resulted in a 2 to 4-fold increase in the total number of tumor-associated apoptotic cells compared with either treatment alone. ZD6126 alone induced apoptosis of tumor-associated endothelial cells in tumors, and the extent of apoptosis was increased 2-fold in combination with cisplatin. The lung weight was significantly reduced, and the number of metastatic nodules significantly was lower in the combined treatment group than in the control group.
CONCLUSIONS: These data suggest that the antimetastatic effect of the vascular-targeting agent ZD6126 can be increased by use in combination with cisplatin, which increases the incidence of endothelial cell apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570000     DOI: 10.1158/1078-0432.CCR-04-1171

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

Review 1.  Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer.

Authors:  Seiji Yano; Yuka Matsumori; Kenji Ikuta; Hirokazu Ogino; Tamir Doljinsuren; Saburo Sone
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

2.  Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.

Authors:  Axel Kleespies; Gudrun Köhl; Michael Friedrich; Anderson J Ryan; Alan Barge; Karl-Walter Jauch; Christiane J Bruns
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

3.  Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis.

Authors:  Ai-Chung Mar; Chun-Ho Chu; Hui-Ju Lee; Chia-Wen Chien; Jing-Jy Cheng; Shung-Haur Yang; Jeng-Kai Jiang; Te-Chang Lee
Journal:  J Biol Chem       Date:  2015-07-24       Impact factor: 5.157

Review 4.  From 3D printing to 3D bioprinting: the material properties of polymeric material and its derived bioink for achieving tissue specific architectures.

Authors:  Nihal Engin Vrana; Sharda Gupta; Kunal Mitra; Albert A Rizvanov; Valeriya V Solovyeva; Ezgi Antmen; Majid Salehi; Arian Ehterami; Lea Pourchet; Julien Barthes; Christophe A Marquette; Magnus von Unge; Chi-Yun Wang; Po-Liang Lai; Arindam Bit
Journal:  Cell Tissue Bank       Date:  2022-01-09       Impact factor: 1.752

5.  A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors.

Authors:  Anne M Traynor; Michael S Gordon; Dona Alberti; David S Mendelson; Mark S Munsey; George Wilding; Richard E Gammans; William L Read
Journal:  Invest New Drugs       Date:  2009-05-13       Impact factor: 3.850

6.  Cisplatin and siRNA interference with structure and function of Wnt-5a mRNA: design and in vitro evaluation of targeting AU-rich elements in the 3' UTR.

Authors:  Margareta Hägerlöf; Pal Papsai; Hanna K Hedman; Ute Jungwirth; Veronika Jenei; Sofi K C Elmroth
Journal:  J Biol Inorg Chem       Date:  2007-12-06       Impact factor: 3.358

7.  Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.

Authors:  A Bozec; S Lassalle; J Gugenheim; J-L Fischel; P Formento; P Hofman; G Milano
Journal:  Br J Cancer       Date:  2006-08-29       Impact factor: 7.640

8.  Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.

Authors:  M Martinelli; K Bonezzi; E Riccardi; E Kuhn; R Frapolli; M Zucchetti; A J Ryan; G Taraboletti; R Giavazzi
Journal:  Br J Cancer       Date:  2007-09-11       Impact factor: 7.640

Review 9.  Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.

Authors:  Marta Cesca; Francesca Bizzaro; Massimo Zucchetti; Raffaella Giavazzi
Journal:  Front Oncol       Date:  2013-10-01       Impact factor: 6.244

10.  Novel analogue of colchicine induces selective pro-death autophagy and necrosis in human cancer cells.

Authors:  Kristen Larocque; Pamela Ovadje; Sinisa Djurdjevic; Mariam Mehdi; James Green; Siyaram Pandey
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.